We offer customizable partnership opportunities to meet your corporate goals, whether it’s brand visibility, thought leadership, or community engagement.

View complete details about the GAPNA Strategic Partners Program.

If you’re ready to elevate your partnership with GAPNA, contact Miriam Martin at miriam.martin@ajj.com or call 856-256-2374. Together, we’ll create a package that aligns with your organization’s goals and delivers maximum value. 

GAPNA thanks our Strategic Partners for their support of our organization.

Platinum Strategic Partners

Eisai

Eisai
6611 Tributary Street, Suite 1
Baltimore, MD  21224
410-631-6300
www.eisai.com

At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.

Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc.
12780 El Camino Real
San Diego, CA 92130
858-617-7600
www.neurocrine.com

Neurology and Endocrinology Research and Therapy | Neurocrine Biosciences

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com.

Additional Resources on Tardive Dyskinesia

Otsuka

Otsuka
508 Carnegie Center Dr,
Princeton, NJ 08540
609-524-6788
www.otsuka-us.com

We place greater value on what we can achieve together than on what we can do alone because the needs of those we serve always come first. We will not be bound by doing what’s been done before. Instead, we free ourselves from preconceived notions to discover solutions that advance patient care. Our mission is clear: Otsuka-people, creating new products for better health worldwide.

Gold Strategic Partners

Sumitomo Pharma America, Inc.

Sumitomo Pharma America, Inc.
84 Waterford Drive
Marlborough, MA 01752
phone: 508-481-6700
www.us.sumitomo-pharma.com

Sumitomo Pharma America (SMPA) is focused on addressing patient needs in oncology, urology, women's health, rare diseases, psychiatry & neurology, and cell & gene therapies. With several marketed products in the U.S., Canada, and Europe, a diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner.

SMPA was formed through the consolidation of Sumitomo Pharma’s U.S. affiliates. Our parent company, the Sumitomo Group, is over 400 years old, with an extensive history of supporting health and wellbeing. SMPA is a Sumitomo Pharma company.